Fact-checked by Grok 2 weeks ago

Small molecule

A small molecule is an organic compound with a low molecular weight, typically under 900 daltons, that can readily permeate cell membranes due to its compact, often hydrophobic structure.^[1] These compounds, distinct from larger biomolecules like proteins or nucleic acids, play essential roles in regulating biological processes by interacting with cellular targets such as enzymes, receptors, or ion channels.^[2] In chemistry and biology, small molecules encompass naturally occurring substances like glucose and amino acids, as well as synthetic entities designed for specific functions.^[1] Key characteristics of small molecules include their chemical stability, ease of synthesis, and ability to be administered orally, making them cost-effective and scalable for production compared to biologics.^[3] They are generally non-immunogenic and exhibit predictable pharmacokinetics, allowing them to target intracellular sites that larger molecules cannot reach.^[4] Over 90% of approved pharmaceuticals are small molecules, highlighting their dominance in therapeutic applications.^[2] Examples include aspirin for pain relief, penicillin as an antibiotic, and imatinib for treating chronic myeloid leukemia.^[1] In drug discovery, small molecules are developed through processes like high-throughput screening and structure-based design, often taking 10–15 years and costing billions to bring to market.^[2] They address a wide range of diseases, from cancer and infectious illnesses to neurological disorders, by modulating protein functions or disrupting pathological pathways.^[5] Advances in computational modeling and artificial intelligence are accelerating their design, promising a resurgence in small-molecule therapeutics amid evolving challenges like drug resistance.^[6]

Definition and Classification

Core Definition

A small molecule is defined as an organic compound with a low molecular weight, typically under 900 daltons, that can readily diffuse across cell membranes due to its compact size and often hydrophobic nature.^[3]^[1] These compounds play essential roles in modulating biological processes, serving as ligands for proteins, enzymes, or receptors to influence cellular functions.^[7] The term "small molecule" gained prominence in the 1990s within the field of drug discovery, particularly as a way to distinguish chemically synthesized organic compounds from emerging biologics like monoclonal antibodies and proteins.^[8] This contrast highlighted the advantages of small molecules in terms of oral bioavailability, cost-effective production, and ease of chemical modification.^[9] Archetypal examples include glucose (molecular weight 180 Da), a fundamental sugar involved in energy metabolism; aspirin (molecular weight 180 Da), a widely used analgesic and anti-inflammatory agent; and adenosine triphosphate (ATP, molecular weight 507 Da), a key energy currency and signaling molecule in cells.^[3]^[1] In broader contexts, small molecules function as modular building blocks in organic synthesis, enabling the construction of complex structures through predictable chemical reactions, while in biology, they underpin essential processes such as metabolism, signaling, and gene regulation.^[9]^[8]

Molecular Weight Cutoff

The molecular weight cutoff for small molecules is conventionally set at less than 900 daltons (Da), a threshold commonly applied to drug-like compounds in pharmaceutical contexts. This limit distinguishes small molecules from larger biomolecules such as proteins or nucleic acids, emphasizing their compact size that facilitates synthesis and biological interaction. The 900 Da boundary reflects empirical observations in drug discovery, where most approved small-molecule therapeutics fall within this range, enabling efficient handling in cheminformatics and screening processes.^[1]^[10] This cutoff is rooted in the biophysical rationale that molecules below approximately 900 Da can typically undergo passive diffusion across biological membranes, such as cell lipid bilayers, without requiring energy-dependent active transport mechanisms. Passive diffusion occurs via simple dissolution into the hydrophobic core of the membrane, driven by concentration gradients, and is favored for smaller, non-polar or moderately polar entities. In contrast, molecules exceeding this weight often exhibit reduced permeability, necessitating carrier proteins or transporters for cellular uptake, which can limit bioavailability and complicate therapeutic delivery. This principle underpins the design of small-molecule drugs to ensure adequate absorption in vivo.^[11]^[12] Variations in the molecular weight cutoff exist depending on the application and context. For oral bioavailability in pharmaceuticals, a stricter limit of less than 500 Da is often enforced, as outlined in Lipinski's Rule of Five, which correlates low molecular weight with favorable pharmacokinetics like absorption and distribution. In broader research settings, such as metabolomics or natural product studies, the threshold may extend up to 1,500 Da to encompass diverse endogenous metabolites while still classifying them as small molecules. These adjustments allow flexibility in non-oral delivery routes or exploratory chemistry.00423-1)^[13] The concept of a molecular weight cutoff has evolved historically from informal practices in early 20th-century pharmacology, where pioneering drugs like aspirin (180 Da) and morphine (285 Da) exemplified small, diffusible entities without explicit size metrics, to formalized standards in modern cheminformatics. The pivotal advancement came with the 1997 publication of Lipinski's Rule of Five, which quantified the 500 Da limit based on analyses of thousands of compounds, influencing drug design globally and shifting from qualitative assessments to data-driven thresholds. This development integrated computational modeling with pharmacological observations, standardizing small-molecule classification amid rising complexity in therapeutic targets.00423-1)^[14]

Distinction from Biomacromolecules

Small molecules are distinguished from biomacromolecules primarily by their non-polymeric nature, lower molecular weights, and mode of production. While small molecules are typically organic compounds with molecular weights below 900–1,000 Da that can be chemically synthesized in laboratories, biomacromolecules such as proteins, nucleic acids, and polysaccharides are large, polymeric structures with molecular weights often exceeding 5,000 Da and are biosynthesized by living organisms through complex enzymatic processes.^[15]^[16] This molecular weight cutoff serves as a primary distinguisher, highlighting the scale difference that influences their biological behaviors and applications.^[15] These structural and synthetic differences confer distinct advantages to small molecules, particularly in terms of mobility and manufacturability. Due to their compact size, small molecules enable rapid diffusion across cell membranes and through tissues, allowing them to access intracellular targets that biomacromolecules cannot reach without specialized transport mechanisms.^[17] Additionally, chemical synthesis facilitates precise tuning of molecular properties, such as solubility or binding affinity, and results in lower production costs compared to the recombinant biologic production required for biomacromolecules, which involves costly cell culture and purification steps.^[18]^[16] Illustrative contrasts appear in biological signaling and therapeutic contexts. For instance, steroid hormones like cortisol, which are small molecules derived from cholesterol, freely diffuse through cell membranes to bind intracellular receptors and regulate gene expression, whereas peptide hormones such as insulin, classified as biomacromolecules, bind to extracellular receptors on the cell surface due to their larger size and polarity. Similarly, in targeted therapies, small molecule inhibitors like imatinib penetrate cells to directly block kinase enzymes, offering advantages in stability and cost over monoclonal antibodies like rituximab, which are large protein-based biomacromolecules that target extracellular antigens but require parenteral administration.^[19] Conceptually, small molecules predominantly act as ligands or effectors that modulate the activity of biomacromolecules, binding to specific sites to influence enzymatic reactions, signaling pathways, or conformational changes, while biomacromolecules often serve as structural scaffolds, providing the foundational frameworks for cellular architecture, catalysis, and information storage in biological systems.^[16] This complementary relationship underscores the unique niches each occupies in biological and pharmaceutical contexts.

Physical and Chemical Properties

Size and Structure

Small molecules typically exhibit diameters on the order of 1 to 3 nm, a scale that permits them to penetrate and occupy narrow hydrophobic pockets within protein structures, which often measure 0.7 to 2 nm across.^[20] This compact size contrasts with larger biomacromolecules and facilitates interactions in confined biological environments, such as enzyme active sites or receptor cavities, where accessibility is limited by steric constraints.^[21] The structural diversity of small molecules arises from their modular assembly of heterocyclic rings—such as pyridines, pyrimidines, and piperidines—and diverse functional groups, including carbonyls, amines, and hydroxyls, which enable a wide range of chemical interactions.^[22] Over 70% of approved small-molecule drugs incorporate at least one aromatic ring, with heterocycles present in more than 50% of cases, contributing to their versatility in mimicking natural substrates or ligands.^[22] Chirality and stereoisomerism further amplify this diversity; more than 56% of marketed small-molecule drugs are chiral, where enantiomers can exhibit markedly different pharmacological profiles due to stereoselective binding to chiral biological targets.^[23] A key aspect of small-molecule structure is the balance between conformational flexibility and rigidity, which influences binding efficiency to macromolecular targets. Flexible molecules with multiple rotatable bonds may adopt varied conformations but incur higher entropic costs upon binding, whereas rigid scaffolds—such as benzene derivatives or fused aromatic systems—preorganize for optimal fit, enhancing affinity by reducing degrees of freedom lost during complex formation.^[24] For instance, rigid benzene-based motifs in inhibitors like those targeting protein-protein interactions stabilize desired conformers, improving selectivity and potency.^[24] To quantify structural complexity, metrics like topological polar surface area (TPSA) and the number of rotatable bonds are commonly employed in drug design. TPSA, calculated as the surface area of polar atoms (nitrogen, oxygen, attached hydrogens), typically ranges from 20 to 130 Å² for orally bioavailable small molecules, reflecting the potential for hydrogen bonding and membrane permeability.^[25] The count of rotatable bonds, indicating conformational freedom, is ideally ≤9 for drug-like compounds, as higher values correlate with increased flexibility and reduced predictability in binding.^[25] These descriptors guide the optimization of small-molecule architectures for therapeutic applications.^[25]

Solubility and Stability

Solubility is a critical physicochemical property of small molecules, determining their ability to dissolve in aqueous or organic solvents, which influences their formulation and biological availability. The octanol-water partition coefficient, expressed as logP, quantifies a small molecule's lipophilicity by measuring the ratio of its concentrations in 1-octanol and water at equilibrium, with values typically ranging from -3 (highly hydrophilic) to +7 (highly lipophilic) for drug-like molecules.^[26] Factors such as hydrogen bonding and ionization significantly affect solubility; polar groups capable of forming hydrogen bonds with water enhance aqueous solubility, while ionization—often pH-dependent—can dramatically increase solubility for weak acids or bases by generating charged species that interact favorably with polar solvents.^[27]^[28] Stability refers to a small molecule's resistance to degradation under various environmental conditions, encompassing thermal, hydrolytic, and oxidative pathways, each modulated by factors like pH and temperature. Thermal stability involves resistance to heat-induced decomposition, often relevant during manufacturing or storage, while hydrolytic stability pertains to resistance against water-mediated cleavage, particularly for ester or amide bonds, with degradation rates accelerating at extreme pH values.^[29] Oxidative stability guards against reactions with reactive oxygen species, commonly affecting amines, thiols, or alkenes, and is influenced by light, metals, or peroxides; pH dependence is pronounced, as acidic or basic conditions can catalyze both hydrolysis and oxidation.^[30]^[31] Examples illustrate these properties: lipophilic small molecules like steroids, such as testosterone with a logP of approximately 3.3, exhibit poor aqueous solubility due to their nonpolar hydrocarbon frameworks but readily partition into lipid environments.^[32] In contrast, hydrophilic small molecules like amino acids, including serine and threonine, possess polar side chains that form hydrogen bonds with water, conferring high aqueous solubility (e.g., serine at approximately 425 g/L at 25°C).^[33] Degradation pathways highlight vulnerabilities; hydrolytic breakdown often occurs via nucleophilic attack on carbonyl groups in esters, yielding carboxylic acids and alcohols, while oxidative pathways may involve electron abstraction from heteroatoms, forming sulfoxides or N-oxides.^[30] These properties directly impact bioavailability, as adequate solubility facilitates absorption across biological membranes, and stability ensures the molecule remains intact during transit.^[34] Instability, such as rapid hydrolysis, often necessitates prodrug design, where inactive precursors are engineered to mask reactive groups, enhancing solubility or stability until enzymatic activation in vivo releases the active form.^[35]

Reactivity and Binding

Small molecules exhibit reactivity primarily through nucleophilic and electrophilic sites, enabling interactions with biological targets. Electrophilic sites, such as α,β-unsaturated carbonyls, act as acceptors for nucleophilic attack by residues like cysteine thiols in proteins, forming covalent bonds via mechanisms like conjugate addition.^[36] Nucleophilic sites on small molecules, including amines or thiols, can similarly engage electrophilic centers on targets, though this is less common in designed inhibitors.^[37] These reactive sites govern the molecule's potential for both covalent and non-covalent interactions, with reactivity tuned by electronic and steric factors; for instance, substituent effects on acrylamides alter second-order rate constants for thiol addition from 10^{-5} to 10^{-3} s^{-1} M^{-1}.^[38] Covalent interactions involve irreversible bond formation, often providing prolonged target engagement and enhanced selectivity compared to non-covalent binding, which relies on reversible associations driven by weaker forces.^[39] Non-covalent binding occurs through hydrogen bonds, which offer directional specificity, and van der Waals forces, which contribute to overall shape complementarity and hydrophobic packing.^[40] The strength of these non-covalent interactions is quantified by the dissociation constant K_d, defined as the ligand concentration at which half the target sites are occupied at equilibrium (K_d = k_{\text{off}} / k_{\text{on}}), where lower values indicate higher affinity; typical K_d ranges for small molecule-protein complexes span micromolar to nanomolar.^[40] Representative examples illustrate these principles. Michael acceptors, such as acrylamide warheads, enable covalent inhibition by undergoing hetero-Michael addition with nucleophilic cysteines, as seen in inhibitors targeting kinase residues with rates enhanced by proximal binding orientations that increase effective molarity up to 18 mM.^[36] In contrast, allosteric modulators exemplify non-covalent binding, attaching to secondary sites distant from active centers to induce conformational changes via hydrogen bonding and van der Waals contacts, such as pyrazinone derivatives modulating metabotropic glutamate receptors with K_d values in the low micromolar range.^[41] Structure-activity relationships (SAR) guide optimization of reactivity and binding by systematically varying molecular features to correlate structural changes with affinity or reactivity metrics. SAR analyses employ descriptors like electronic substitution patterns to predict improvements in K_d or reaction rates, enabling iterative design; for example, modifying warhead electronics in electrophiles can shift activity cliffs, where minor alterations yield potency gains of orders of magnitude.^[42] This approach prioritizes balanced reactivity to avoid off-target effects while enhancing target-specific binding.^[42]

Natural Occurrence and Biosynthesis

Secondary Metabolites

Secondary metabolites are organic compounds produced by living organisms, such as plants, fungi, and bacteria, that are not directly involved in essential processes like growth, development, or reproduction, but instead fulfill ecological functions including defense against predators and pathogens or attraction of beneficial organisms.^[43] Unlike primary metabolites, which are universally required for basic cellular functions, secondary metabolites are synthesized during specific growth phases, often in response to environmental stresses, and derive from modifications of primary metabolic precursors.^[44] Major classes include alkaloids (nitrogen-containing compounds), terpenoids (derived from isoprene units), and phenolics (aromatic compounds with hydroxyl groups).^[45] Representative examples illustrate their roles: caffeine, an alkaloid produced by coffee plants (Coffea species), acts as a chemical defense by deterring herbivores and insects through its toxicity and bitterness.^[46] Similarly, penicillin, a beta-lactam antibiotic generated by certain fungi like Penicillium chrysogenum, inhibits bacterial cell wall synthesis to provide protection against competing microbes in the environment.^[47] Over 100,000 distinct secondary metabolites have been identified across organisms, reflecting immense chemical diversity that arises from variations in biosynthetic pathways.^[44] These compounds are often classified based on their origins: phenolics typically stem from the shikimate pathway, which generates aromatic precursors like phenylalanine, while terpenoids are produced via the mevalonate pathway involving acetyl-CoA condensation.^[45] Alkaloids, meanwhile, incorporate nitrogen from amino acids such as tryptophan or tyrosine. This biosynthetic diversity enables organisms to generate specialized molecules tailored to niche ecological pressures. Ecologically, secondary metabolites mediate key interactions, such as antibiosis—where compounds like penicillin suppress microbial competitors—or attraction of pollinators through volatile terpenoids and colorful phenolics that signal rewards in flowers.^[43] For instance, nectar containing secondary metabolites can enhance pollinator fidelity while deterring nectar robbers.^[48] From an evolutionary perspective, these metabolites have driven adaptation by providing selective advantages in defense, symbiosis, and resource competition, with gene cluster expansions in biosynthetic pathways reflecting phylogenetic divergence among species.^[49] Over time, this has led to the co-evolution of producer organisms and their interactors, such as herbivores developing resistance countered by metabolite diversification.^[50]

Endogenous Small Molecules

Endogenous small molecules are low-molecular-weight organic compounds synthesized within cells of living organisms to support vital physiological processes, distinguishing them from exogenous or synthetic counterparts. These molecules are integral to cellular homeostasis, enabling communication, metabolism, and adaptation to internal and external cues. Unlike secondary metabolites, which often serve non-essential ecological roles, endogenous small molecules are indispensable for core survival functions. Their diversity spans multiple chemical classes, including lipids that form structural components of membranes and store energy; nucleotides that participate in signaling and genetic information transfer; and vitamins that serve as precursors for essential coenzymes. For example, phospholipids as lipids maintain membrane integrity, ATP as a nucleotide acts as the primary energy carrier, and niacin-derived vitamins enable cofactor synthesis for enzymatic reactions.^[51]^[52]^[53] Key examples illustrate their functional breadth: hormones such as adrenaline (epinephrine) trigger swift responses like increased heart rate during stress; neurotransmitters including dopamine mediate synaptic transmission for mood and motor control; and cofactors like NAD⁺ (nicotinamide adenine dinucleotide) facilitate electron transfer in metabolic pathways. These molecules operate at dynamic concentrations, typically in the nanomolar to micromolar range, fluctuating in response to cellular needs to optimize efficiency.^[54]^[55]^[56] In terms of roles, endogenous small molecules drive signaling by binding receptors to propagate messages across cells, as seen with hormones and neurotransmitters; enable energy transfer through redox reactions involving cofactors like NAD⁺; and exert regulation by modulating enzyme activity and gene expression to fine-tune metabolism. Concentration dynamics are governed by intricate feedback loops, such as negative feedback that inhibits overproduction once a threshold is reached, ensuring stability amid varying demands.^[57]^[58] Dysregulation of these systems underlies pathological conditions; for instance, in diabetes, disruption of insulin signaling—relaying through small-molecule second messengers like phosphatidylinositol (3,4,5)-trisphosphate—impairs glucose uptake and leads to hyperglycemia. Such imbalances highlight the precise orchestration required for health, with feedback loops acting as safeguards against metabolic chaos.^[59]

Biosynthetic Pathways

Biosynthetic pathways in living organisms encompass a series of enzymatic reactions that assemble small molecules from simpler precursors, essential for cellular function and adaptation. These pathways are broadly classified into primary and secondary categories, with primary pathways supporting core metabolic needs and secondary pathways generating specialized compounds often with ecological roles.^[60] Primary biosynthetic pathways include glycolysis, which converts glucose into pyruvate, yielding energy intermediates like ATP and NADH while producing small sugar-derived molecules such as glyceraldehyde-3-phosphate. This ancient pathway operates anaerobically in nearly all organisms, linking carbohydrate catabolism to downstream processes.^[61] Fatty acid synthesis represents another key primary route, initiating with the carboxylation of acetyl-CoA to malonyl-CoA by acetyl-CoA carboxylase, followed by iterative condensation and reduction steps in the cytosol of eukaryotic cells to form saturated fatty acids like palmitate, a 16-carbon chain critical for membrane lipids.^[62]^[63] Secondary biosynthetic pathways, in contrast, produce diverse small molecules beyond essential growth requirements, often in response to environmental cues. Polyketide synthases (PKSs) assemble polyketides through modular enzyme complexes that catalyze decarboxylative condensations of malonyl-CoA units, akin to fatty acid synthesis but with variable reduction, yielding compounds like antibiotics and pigments.^[60] Non-ribosomal peptide synthetases (NRPSs) synthesize peptides independently of ribosomes, using adenylation domains to activate amino acids and peptidyl carrier proteins for sequential assembly, resulting in structurally complex small molecules such as siderophores and toxins.^[64] These pathways are widespread across bacteria, fungi, and plants, with NRPS and PKS gene clusters commonly co-occurring in actinomycetes.^[65] Key enzymes exemplify the precision of these routes; for instance, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase catalyzes the rate-limiting reduction of HMG-CoA to mevalonate in the mevalonate pathway, a branch of primary metabolism dedicated to isoprenoid and cholesterol biosynthesis in eukaryotes.^[66] This enzyme's activity commits precursors toward sterol production, highlighting how single steps can gate entire metabolic branches.^[67] Regulation of biosynthetic pathways ensures metabolic balance, employing allosteric control where metabolites bind enzyme sites distant from the active center to modulate activity, as seen in feedback inhibition of amino acid pathways to prevent overaccumulation.^[68] Gene expression provides another layer, with transcription factors responding to nutrient availability to upregulate or repress pathway genes, optimizing flux under varying conditions.^[69] These mechanisms exhibit evolutionary conservation, with regulatory architectures refined over billions of years to align enzyme levels with physiological demands, as evidenced in conserved transcriptional networks across prokaryotes and eukaryotes.^[70] Such pathways yield endogenous small molecules that serve as signaling agents, cofactors, and structural components within cells.^[60]

Applications in Biology and Medicine

Drug Development

Small molecule drug development primarily involves identifying and refining chemical compounds that can modulate biological targets to treat diseases. The process typically begins with high-throughput screening (HTS), where large libraries of small molecules—often numbering in the millions—are tested against a target protein or cellular assay to identify initial "hits" that show promising activity.^[71] These hits are then subjected to lead optimization, an iterative phase where medicinal chemists modify the molecule's structure to enhance potency, selectivity, and pharmacokinetic properties while minimizing toxicity.^[71] Throughout this stage, absorption, distribution, metabolism, and excretion (ADME) profiling is integrated early and frequently using high-throughput assays to predict how the drug will behave in vivo, ensuring candidates meet criteria like oral bioavailability and a molecular weight typically under 500 Da for drug-likeness.^[72] This systematic approach has enabled the approval of numerous therapeutics, with small molecules comprising approximately 60-70% of recent FDA-approved pharmaceuticals (as of 2025) due to their synthetic accessibility and broad applicability.^[73]^[74] Representative examples illustrate the success of these processes. Statins, such as lovastatin and atorvastatin, emerged from screening fungal metabolites that inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis; initial discovery in the 1970s by Akira Endo at Sankyo Co. led to lead optimization yielding potent, orally active agents that revolutionized cardiovascular treatment.^[75] Similarly, paclitaxel, a diterpenoid isolated from the Pacific yew tree bark in the 1960s by the U.S. National Cancer Institute, underwent extensive optimization to become a cornerstone chemotherapy drug; it stabilizes microtubules to arrest cancer cell division, demonstrating how natural product-derived small molecules can be refined for clinical use in ovarian, breast, and lung cancers.^[76] Compared to biologics like monoclonal antibodies, small molecule drugs offer key advantages, including ease of oral administration—which improves patient compliance—and lower production costs due to scalable chemical synthesis rather than complex biologics manufacturing.^[6] These factors contribute to their market dominance and development timelines typically spanning 10-15 years, comparable to or slightly shorter than those for biologics.^[2]^[77] However, challenges persist, such as off-target effects that can cause unintended toxicity by binding non-target proteins, and the development of drug resistance through mechanisms like target mutation or efflux pump upregulation in pathogens and tumors.^[78] Since the early 2000s, trends toward personalized medicine have addressed these issues by incorporating genomic profiling to tailor small molecule therapies, improving efficacy in heterogeneous diseases like cancer while reducing adverse events.^[79]

Anti-Genomic Therapeutics

Anti-genomic therapeutics encompass small molecules engineered to modulate gene expression and genomic functions by targeting epigenetic machinery, protein regulators, or editing processes, offering precise interventions beyond traditional nucleic acid-based approaches. These agents address limitations in conventional therapies by interfering with genomic stability, transcription, and post-transcriptional regulation, particularly in diseases like cancer where aberrant gene expression drives pathogenesis. Unlike broad-spectrum drugs, anti-genomic small molecules often achieve specificity through selective inhibition or recruitment mechanisms, enabling durable changes in cellular phenotypes without altering the DNA sequence itself.^[80] A primary mechanism involves histone deacetylase (HDAC) inhibitors, which promote chromatin accessibility and gene reactivation by blocking HDAC enzymes that remove acetyl groups from histones, thereby countering epigenetic silencing in tumors. Vorinostat, an FDA-approved HDAC inhibitor, exemplifies this class by restoring expression of silenced tumor suppressor genes in cutaneous T-cell lymphoma through hyperacetylation of histones, leading to cell cycle arrest and apoptosis.^[81] Another key strategy employs proteolysis-targeting chimeras (PROTACs), bifunctional small molecules that recruit E3 ubiquitin ligases to transcription factors, inducing their ubiquitination and proteasomal degradation to disrupt oncogenic transcriptional programs. For instance, PROTACs targeting BET family transcription factors have shown efficacy in preclinical models of prostate cancer by depleting BRD4, a key epigenetic reader that sustains aberrant gene expression.^[82] As of 2025, PROTAC-based candidates like ARV-471 (vepdegestrant) have reported positive Phase 3 results, demonstrating tumor regression in estrogen receptor-positive breast cancer via selective protein elimination.^[83] These mechanisms highlight how small molecules can reprogram the epigenome or eliminate key genomic regulators catalytically, amplifying therapeutic impact at sub-stoichiometric doses.^[84] Small molecules also enhance genome editing technologies, such as CRISPR-Cas9, by boosting homology-directed repair (HDR) efficiency to favor precise insertions over error-prone non-homologous end joining. Compounds like SCR7 inhibit DNA ligase IV to suppress non-HDR pathways, increasing knock-in precision in human cells by up to threefold, as demonstrated in pluripotent stem cell models.^[85] As alternatives to antisense oligonucleotides, small molecule modulators of microRNAs (miRNAs) mimic or inhibit miRNA functions to regulate gene networks; for example, compounds like AC1MMYR2 inhibit miR-21 biogenesis, reducing oncogenic signaling in glioblastoma models by blocking miRNA maturation.^[86] Post-2010 advancements have introduced small molecule-inducible epigenome editors, such as Chem-CRISPR systems where ligands like JQ1 recruit deactivated Cas9 fused to epigenetic effectors, enabling transient, chemically controlled methylation or acetylation at specific loci for reversible gene silencing.^[87] These innovations, including light- or ligand-inducible platforms, expand the toolkit for targeted epigenome modulation.^[88] In clinical contexts, anti-genomic small molecules have advanced to trials for cancer, with HDAC inhibitors like vorinostat combined with immunotherapy showing prolonged progression-free survival in advanced solid tumors by enhancing antitumor immune responses through epigenetic reprogramming.^[89] A distinctive advantage of these small molecules lies in circumventing delivery challenges associated with nucleic acid therapeutics, such as poor cellular uptake and immune activation, due to their favorable pharmacokinetics and oral bioavailability. Furthermore, they hold promise for anti-viral applications by interfering with viral genome integration or latency; for instance, HDAC inhibitors disrupt HIV proviral transcription in latent reservoirs, reactivating the virus for subsequent clearance in "shock and kill" strategies.^[90] Ongoing trials explore such agents against hepatitis B virus by targeting epigenetic maintenance of cccDNA minichromosomes.^[91]

Research and Screening Tools

Small molecules serve as versatile probes in biological research, enabling the visualization and manipulation of cellular processes at the molecular level. Fluorescent dyes, such as fluorescein, are widely used to label biomolecules and track dynamic events like protein localization and enzyme activity in live cells. These dyes exploit their inherent reactivity to form covalent bonds with target molecules, facilitating non-invasive imaging techniques. Similarly, small molecule inhibitors, exemplified by kinase inhibitors like staurosporine, allow researchers to dissect signaling pathways by selectively blocking enzyme function, thereby revealing causal relationships in cellular responses.^[92] In chemical genetics, small molecules act as tunable tools to mimic genetic perturbations, offering advantages over traditional genetic knockouts due to their rapid action and reversibility. This approach has been pivotal in phenotypic screening, where libraries of small molecules are screened to identify compounds that induce specific cellular phenotypes, such as changes in morphology or proliferation. High-content imaging further enhances these applications by integrating automated microscopy with small molecule probes to quantify multiple parameters simultaneously, enabling large-scale analysis of compound effects on cellular architecture and function. Key methodologies like click chemistry have revolutionized small molecule labeling by providing bioorthogonal reactions that efficiently attach probes to targets without interfering with native biology; for instance, azide-alkyne cycloadditions enable precise tagging in complex cellular environments. Complementing this, diversity-oriented synthesis (DOS) generates structurally diverse small molecule libraries, expanding the chemical space for discovering novel research tools beyond natural products. Since 2020, advancements in AI-driven design have accelerated the creation of bespoke probes, using machine learning models trained on vast chemical datasets to predict and optimize molecules for specific binding affinities and optical properties, thus filling gaps in traditional screening efficiency.

Synthesis and Production Methods

Chemical Synthesis

Chemical synthesis of small molecules involves the construction of organic compounds through laboratory-based reactions, often designed to mimic or surpass natural biosynthetic efficiency while enabling precise structural control. This approach contrasts with biological pathways by relying on human-engineered conditions, reagents, and catalysts to assemble carbon skeletons from simple precursors. Key methods include named organic reactions and multi-step sequences tailored for complexity and yield.^[93] A pivotal historical milestone in small molecule synthesis occurred in the 1950s with Robert B. Woodward's pioneering total syntheses, exemplified by the collaborative effort to synthesize vitamin B12, a corrin-based molecule with 9 chiral centers. Completed in 1972 after years of work involving over 90 researchers, this achievement demonstrated the feasibility of constructing highly complex natural products through sequential organic transformations, including cyclizations and condensations, marking a shift toward systematic total synthesis as a cornerstone of organic chemistry.^[94] Modern strategies emphasize efficiency and diversity, with cross-coupling reactions like the Suzuki-Miyaura coupling serving as a workhorse for forming carbon-carbon bonds in heterocyclic small molecules. This palladium-catalyzed process couples aryl or vinyl boronic acids with halides, enabling the rapid assembly of biaryls and polyheterocycles central to pharmaceuticals, as evidenced by its frequent use in medicinal chemistry pipelines where it accounts for a significant portion of C-C bond formations.^[93]^[95] Multi-component reactions (MCRs) further streamline synthesis by combining three or more reactants in a single pot to generate complex scaffolds, reducing steps and waste compared to sequential approaches. For instance, the Ugi reaction integrates amines, aldehydes, carboxylic acids, and isocyanides to produce α-aminoacyl amides, a versatile class of small molecules used in drug-like libraries. These reactions enhance atom economy and have been pivotal in generating structural diversity for biological screening.^[96]^[97] Total synthesis remains essential for validating structures and exploring analogs, as seen in Woodward's era, but has evolved with combinatorial chemistry to produce libraries of small molecules. This strategy employs iterative reactions on solid supports or in solution to generate thousands of variants, facilitating high-throughput discovery of bioactive compounds without individual optimization. Early implementations in the 1990s focused on non-peptidic heterocycles, expanding chemical space beyond natural products.^[98]^[99] Catalysts play a crucial role in enabling selective transformations, with advancements in asymmetric catalysis highlighted by Nobel Prizes from 2001 to 2021. The 2001 award recognized Knowles, Noyori, and Sharpless for chiral hydrogenation and epoxidation methods that produce enantiopure small molecules vital for therapeutics. Subsequent honors in 2005 (metathesis), 2010 (Heck, Negishi, Suzuki cross-couplings), and 2021 (List and MacMillan for organocatalysis) underscore the shift toward metal- and organo-catalysts that achieve high enantioselectivity in C-C and C-O bond formations, minimizing racemization in drug synthesis.^[100] Green chemistry principles guide sustainable practices in small molecule synthesis, prioritizing atom economy, safer solvents, and renewable feedstocks to reduce environmental impact. For example, the avoidance of protecting groups and use of catalytic processes align with these tenets, as implemented in pharmaceutical routes where process mass intensity is minimized.^[101] Automation via continuous-flow synthesis enhances precision and scalability in laboratories, allowing real-time monitoring and rapid iteration for small molecule production. Flow reactors facilitate reactions like cross-couplings under controlled conditions, improving safety for exothermic processes and enabling multistep sequences without manual intervention.^[102]^[103]

Biotechnological Production

Biotechnological production of small molecules involves the use of genetically engineered organisms to biosynthesize these compounds at scale, leveraging biological pathways for efficient and sustainable manufacturing. This approach integrates metabolic engineering, where cellular metabolism is rewired to optimize precursor availability and flux toward target molecules, and directed evolution, which iteratively mutates and selects enzymes for enhanced catalytic efficiency in biosynthetic cascades. For instance, metabolic engineering has enabled the reconstruction of complex pathways in microbial hosts, allowing production of pharmaceuticals that are challenging to synthesize chemically. A landmark example is the production of artemisinin, an antimalarial small molecule, through engineered Saccharomyces cerevisiae. In 2013, researchers introduced a multi-gene pathway from Artemisia annua into yeast, achieving titers of 25 g/L artemisinic acid, a direct precursor convertible to artemisinin via simple chemistry, thereby stabilizing supply amid fluctuating plant harvests. Similarly, directed evolution has been applied to refine enzymes like cytochrome P450s in these pathways, boosting conversion rates and reducing side reactions. For glycopeptide antibiotics, metabolic engineering in actinomycetes such as Amycolatopsis balhimycina has optimized the shikimate pathway to enhance production, yielding over 4-fold increased titers of balhimycin.^[104]^[105] Plant cell cultures represent another key technique, particularly for terpenoid small molecules like taxol (paclitaxel), a chemotherapeutic agent. Engineered Taxus cell lines, through overexpression of rate-limiting enzymes such as taxadiene synthase, have achieved yields of up to 100 mg/L in bioreactors, circumventing the low extraction efficiency from yew tree bark. CRISPR-based editing further amplifies these efforts by precisely knocking out competing pathways or upregulating transporters, as demonstrated in fungal hosts where Cas9-mediated modifications increased terpenoid yields by 50-100%. These methods address supply chain vulnerabilities for complex natural products, such as seasonal variability in plant sourcing, by enabling consistent, on-demand microbial or cell-based fermentation.^[106]^[107] The 2010s marked a biotech boom in these technologies, driven by advances in synthetic biology and genome editing, which have scaled production of over 20 natural product-derived small molecules, including antibiotics and anticancer agents, reducing reliance on environmentally taxing extraction processes. Compared to chemical synthesis, biotechnological routes offer greater sustainability through renewable feedstocks and lower energy inputs, particularly for stereochemically intricate structures.

Industrial Scaling

Industrial scaling of small molecule production involves transitioning from laboratory or pilot-scale processes to large-volume manufacturing that meets commercial demands while adhering to regulatory standards. Key processes include the use of continuous flow reactors, which enable safer handling of hazardous reactions at scale by maintaining small reaction volumes and precise control over temperature and mixing, as demonstrated in implementations by pharmaceutical companies like Pfizer and Eli Lilly.^[108]^[109] Crystallization serves as a primary purification technique, isolating the target molecule from impurities through controlled precipitation and filtration, often integrated into continuous systems for efficiency.^[110] All industrial production must comply with Good Manufacturing Practice (GMP) guidelines, ensuring product quality, safety, and traceability, as outlined in FDA's quality considerations for continuous manufacturing of small molecule solid oral dosage forms.^[111] Challenges in industrial scaling encompass stringent impurity control to meet pharmacopeial limits, often requiring advanced analytical monitoring and process adjustments to avoid carryover from reagents or byproducts. Yield optimization is critical, as scale-up can introduce inefficiencies like heat transfer limitations or mixing inconsistencies, potentially reducing overall efficiency from 90% at lab scale to 70-80% industrially. Cost analysis remains a pivotal factor, with active pharmaceutical ingredient (API) production costs typically ranging from $1 to $10 per gram, influenced by raw material prices, energy consumption, and facility overheads; for example, the API cost for dexamethasone was estimated at approximately $1.12 per gram between 2016 and 2020.^[112]^[113]^[114] Representative examples illustrate successful scaling, such as the production of ibuprofen in pharmaceutical plants using continuous flow synthesis, which has enabled annual outputs exceeding thousands of tons since the drug's patent expiry in 1985, supporting global generic supply. Post-patent expiry scaling for generics, like atorvastatin after 2011, has dramatically increased production volumes through optimized batch and continuous processes, reducing costs by up to 80% and expanding access in emerging markets.^[115]^[116] In the 2020s, trends emphasize sustainable processes, including the integration of biocatalysis to enhance environmental performance by reducing waste and solvent use in API synthesis, as seen in over 130 approved small molecule drugs incorporating enzymatic steps. The COVID-19 pandemic highlighted vulnerabilities in global supply chains, with disruptions from factory shutdowns in key regions like China causing shortages of essential small molecule APIs and prompting a shift toward diversified, resilient manufacturing networks.^[115]^[117]^[118]

References

[1]
Small Molecule - an overview | ScienceDirect Topics
A small molecule is an organic compound, usually hydrophobic, having a low molecular weight (generally, < 1000 Da).
[2]
Introduction to small molecule drug discovery and preclinical ...
Nov 29, 2023 · Small molecule drugs are synthetic medicinal chemicals designed to mimic, enhance, or diminish the behaviour of natural substances or ...
[3]
What are Small Molecule Drugs? - Patheon pharma services
Oct 28, 2024 · Small-molecule drugs are low-molecular-weight compounds, typically under 900 daltons, that can be chemically synthesized or derived from natural sources.
[4]
Paving the way for small-molecule drug discovery - PubMed Central
Small-molecule drugs are organic compounds affecting molecular pathways by targeting important proteins, which have a low molecular weight, making them ...
[5]
Discovery of small molecule cancer drugs: Successes, challenges ...
In this review we provide an overview of contemporary approaches to the discovery of small molecule cancer drugs, highlighting successes, current challenges ...
[6]
Artificial Intelligence in Small-Molecule Drug Discovery - NIH
Aug 26, 2025 · These approaches have demonstrated the ability to generate millions of novel drug-like small molecules while maintaining synthetic accessibility ...
[7]
Small molecules - AstraZeneca
Defined as any organic compound with low molecular weight, small molecule drugs have some distinct advantages as therapeutics: most can be administered orally ...
[8]
Chemical probes and drug leads from advances in synthetic ...
The use of small-molecule screening in early-stage drug discovery expanded dramatically in the 1990s with the introduction of new screening technologies and ...
[9]
Small molecules and their impact in drug discovery: A perspective ...
Bayer celebrates its long history in small molecule drug discovery. •. Small molecule drugs have always played a major role in the progress of medicine.
[10]
[PDF] Regulatory Knowledge Guide for Small Molecules | NIH's Seed
Small molecule drugs, regulated by the FDA, are organic compounds with a molecular weight around or below 900 Daltons, and are reviewed by the FDA's CDER.
[11]
Passive Diffusion - an overview | ScienceDirect Topics
The molecular size of a chemical: Passive diffusion is normally limited to molecules whose molecular weight does not exceed 500 Da. However, a small molecule ...
[12]
Getting Across the Cell Membrane: An Overview for Small Molecules ...
Passive diffusion across a cellular membrane is driven by the concentration and electric gradient of the solute and does not require the use of energy. In the ...Missing: cutoff | Show results with:cutoff
[13]
Small molecule metabolites: discovery of biomarkers and ... - Nature
Mar 20, 2023 · Metabolome covers a suite of small metabolites with a molecular mass less than 1500 Da, including but not limited to amino acids, lipids ...
[14]
Two Decades under the Influence of the Rule of Five and the ...
This author would posit that since the average molecule weight of FDA approved oral drugs has exceeded the 500 “limit” for 2 consecutive years, the medicinal ...
[15]
Small Molecules vs. Biologics: Key Drug Differences - Allucent
We discuss similarities and differences between these two therapeutic categories and important points to consider during drug development.
[16]
Clinical pharmacology considerations in biologics development - PMC
Sep 24, 2012 · The primary distinctions between biologics and small molecule drugs are their sizes, structural complexity and how they are produced. The ...
[17]
Cell Membranes - The Cell - NCBI Bookshelf - NIH
Only small uncharged molecules can diffuse freely through phospholipid bilayers (Figure 2.49). Small nonpolar molecules, such as O2 and CO2, are soluble in the ...<|control11|><|separator|>
[18]
What are the drugs of the future? - PMC - NIH
Apr 23, 2018 · Are small molecules or biologics the drugs of the future? Small-molecule drugs have historically been the pillars of traditional medicine.
[19]
From monoclonal antibodies to small molecules: the development of ...
When compared with mAbs, small drug-like inhibitors have many other benefits; for example, they are cheaper, more stable, better for organ or tumor ...
[20]
Small-molecule ligands bind to a distinct pocket in Ras and inhibit ...
The compounds show amphipathic interactions centering on a hydrophobic pocket of approximately 7 × 7 Å at the opening and 5-Å deep (Fig.
[21]
A Comprehensive Survey of Small-Molecule Binding Pockets ... - NIH
Oct 24, 2013 · On average, 28%, 22%, and 4% of interactions are hydrophilic, hydrophobic, or aromatic, respectively; the remaining are either neutral (or ...
[22]
Chemical Structure-Related Drug-Like Criteria of Global Approved ...
Jan 12, 2016 · Ring systems and functional groups are important components of a drug. The proportion of non-hydrocarbon atoms among non-hydrogen atoms reflects ...
[23]
Chiral Drugs: An Overview - PMC - PubMed Central
Sulfur, phosphorus and nitrogen can sometimes form chiral molecules such as omeprazole, cyclophosphamide and methaqualone, respectively. Chiral molecules ...
[24]
Importance of Rigidity in Designing Small Molecule Drugs To Tackle ...
(48) Small molecules can bind to the protein at allosteric sites and shift the equilibrium of conformer sampling so that binding can influence the overall ...
[25]
SwissADME: a free web tool to evaluate pharmacokinetics, drug ...
Mar 3, 2017 · The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar ...
[26]
Octanol-Water Partition Coefficient - an overview - ScienceDirect.com
The octanol water partition coefficient is defined as the ratio of a chemical's concentration in the octanol phase to its concentration in the aqueous phase ...
[27]
6.3: Hydrogen Bonding Interactions and Solubility
Apr 2, 2022 · The stronger the interactions between solute and solvent molecules, the greater the likelihood that solubility will increase.
[28]
Physicochemical Properties in Relation to Biological Action
Intermolecular hydrogen bonding raises the compound's boiling point and makes it more water soluble. Solubility of molecules may be improved by intermolecular ...
[29]
Understanding the chemical basis of drug stability and degradation
Oct 9, 2010 · The main chemical reactions that affect the stability of a drug are oxidation and hydrolysis. Oxidation involves the removal of electrons from ...
[30]
Drug degradation pathways - Pharmaceutical - Pharmacy 180
Major degradation pathways include hydrolysis, oxidation, and photolysis. Hydrolysis. Hydrolysis is the common degradation pathway of carboxylic acid ...Hydrolysis · Oxidation · Chapter: Pharmaceutical...
[31]
An Approach to Drug Stability Studies and Shelf-life Determination
Aug 8, 2025 · pH and temperature are the main factors influencing the stability of the drug. The pH-rate profile (log(k)vs pH) is the pH dependence of the ...
[32]
Systematic Study of Steroid Drugs' Ability to Cross Biomembranes ...
Thirty-seven steroid drugs of different types were investigated in silico for their environmental and pharmacokinetic properties.
[33]
amino acid | Learn Science at Scitable - Nature
For example, some amino acids have polar side chains that are soluble in water; examples include serine, threonine, and asparagine. Other amino acids avoid ...Missing: hydrophilic | Show results with:hydrophilic
[34]
Overcoming Challenges in Small-Molecule Drug Bioavailability - MDPI
Key factors influencing bioavailability include aqueous solubility ... hydrogen bonding and conformational flexibility can enable unexpectedly high oral ...2.1. Physicochemical... · 2.1. 1. Solubility · 2.2. Biological Factors<|control11|><|separator|>
[35]
Prodrugs for Improved Drug Delivery: Lessons Learned from ... - NIH
Oct 29, 2020 · The prodrug approach is used to overcome biopharmaceutic, pharmacokinetic, or pharmacodynamic obstacles, including poor chemical stability, ...
[36]
Covalent Ligand Electrophiles Are Differentially Activated by ...
Sep 8, 2025 · Covalent ligands contain an electrophilic moiety that reacts with a nucleophilic residue on a target protein, following an initial ...
[37]
REACTIONS OF ELECTROPHILES WITH NUCLEOPHILIC ...
Jan 1, 2017 · This review will focus on electrophile interactions with cysteine thiolates and the pathophysiological consequences that result from irreversible electrophile ...
[38]
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β ...
Small-molecules bearing a variety of different Michael acceptors have also been used as chemical biology tools for elucidating biological pathways. Activity ...
[39]
The resurgence of covalent drugs | Nature Reviews Drug Discovery
Covalent drugs block protein function by forming a specific bond between the ligand and target protein. A covalent mechanism of action can provide many ...
[40]
How to measure and evaluate binding affinities - eLife
Aug 6, 2020 · Kinetic approach to affinity determination. An equilibrium dissociation constant is the ratio of dissociation and binding rate constants (KD ...
[41]
Allosteric Modulators: An Emerging Concept in Drug Discovery - PMC
In this approach, small molecule drugs are designed to bind into secondary binding sites on the targeted biomolecules rather than the main orthosteric sites.
[42]
On Exploring Structure Activity Relationships - PMC - NIH
May 2, 2016 · Structure-activity relationships (SAR) are key to many aspects of drug discovery, ranging from primary screening to lead optimization.
[43]
Secondary Metabolite - an overview | ScienceDirect Topics
Thus, secondary metabolites may be redefined as compounds which are not essential for exponential growth. Secondary metabolites are biosynthesized from a ...
[44]
From Nature to Lab: A Review of Secondary Metabolite Biosynthetic ...
Chorismate is the final product in the seven-step pathway of shikimic acid, and it serves as the starting material for the biosynthesis of secondary metabolites ...
[45]
Plant Secondary Metabolite Biosynthesis and Transcriptional ... - MDPI
Based on biosynthesis pathways, SMs can be divided into three main groups: phenolic compounds synthesized in the shikimate pathway, terpenes synthesized in the ...
[46]
Caffeine Extraction, Enzymatic Activity and Gene Expression of ... - NIH
Oct 2, 2018 · This secondary metabolite is regarded as a chemical defense because it has antimicrobial activity and is considered a natural insecticide.
[47]
Physiological characterization of secondary metabolite producing ...
Oct 17, 2017 · The most well-known secondary metabolite produced by Penicillium is the antibiotic penicillin, which was discovered by Fleming [3] and which is ...
[48]
Plant secondary metabolites in nectar: impacts on pollinators and ...
Sep 7, 2016 · It is possible that their occurrence in nectar is regulated for ecological functions: to enhance pollination service or protect the flower and/or pollinator ...Summary · Occurrence of secondary... · Role of secondary metabolites...
[49]
(PDF) Evolution of Secondary Metabolites from an Ecological and ...
Aug 6, 2025 · Secondary metabolites can protect plants against herbivores, bacteria, viruses, or competing plants, and act as signaling compounds to attract ...
[50]
The Evolution of Function in Plant Secondary Metabolites
Evolutionary and ecological studies of plant secondary metabolites have been closely linked because of the early recognition that many of these compounds ...Missing: antibiosis | Show results with:antibiosis
[51]
Biochemistry, Lipids - StatPearls - NCBI Bookshelf - NIH
May 1, 2023 · Fats and lipids are an essential component of the homeostatic function of the human body. Lipids contribute to some of the body's most vital ...Biochemistry, Lipids · Mechanism · Clinical Significance
[52]
Nucleic Acid Precursor - an overview | ScienceDirect Topics
The nucleotides can serve as nucleic acid precursors and exogenous sources of purine and pyrimidine bases.
[53]
2.2: Vitamins as Coenzymes - Medicine LibreTexts
Nov 16, 2021 · Water-soluble vitamins are precursors of coenzymes for the enzymes of intermediary metabolism. Fat-soluble vitamins. Fat-soluble vitamins ...
[54]
[PDF] Hormones are small molecules or proteins that are produced in one ...
Hormones are small molecules or proteins that are produced in one tissue, released into the bloodstream, and carried to other tissues, where they act.
[55]
The Endocrine Brain: Pathophysiological Role of Neuropeptide ...
Within the category of small-molecule neurotransmitters, the biogenic amines (dopamine, nor-epinephrine, epinephrine, serotonin, and histamine) are often ...
[56]
NAD+ metabolism and its roles in cellular processes during ageing
In addition to energy metabolism, NAD+ is used as a cofactor or substrate by hundreds of enzymes and therefore has multiple roles in the regulation of cellular ...
[57]
Small molecule signaling, regulation, and potential applications in ...
Small molecules have many important roles across the tree of life: they regulate processes from metabolism to transcription, they enable signaling within and ...
[58]
Combinatorics of feedback in cellular uptake and metabolism of ...
Dec 26, 2007 · Our analysis of two entangled feedback loops creates a framework for analyzing small molecule regulatory circuits composed of multiple entangled ...
[59]
The dynamic clustering of insulin receptor underlies its signaling ...
Dec 6, 2022 · Insulin receptor (IR) signaling is central to normal metabolic control and is dysregulated in metabolic diseases such as type 2 diabetes.
[60]
Surveys of Non-Ribosomal Peptide and Polyketide Assembly Lines ...
Biosynthetic products span from essential primary metabolites such as fatty acids that make up the cell membrane to polyketides (PKs) and nonribosomal peptides ...
[61]
Biochemistry, Glycolysis - StatPearls - NCBI Bookshelf - NIH
Glycolysis is a metabolic pathway and an anaerobic energy source that has evolved in nearly all types of organisms.Missing: biosynthetic fatty
[62]
The Biosynthesis of Cell Constituents - NCBI - NIH
The major product of fatty acid biosynthesis, which occurs in the cytosol of eukaryotic cells, is the 16-carbon fatty acid palmitate. The principal ...Missing: small | Show results with:small
[63]
Fatty Acid Biosynthesis Revisited: Structure Elucidation and ...
Typically, fatty acid biosynthesis begins with acetyl-CoA, carboxylation produces the malonyl-CoA building blocks that are subsequently condensed and reduced in ...
[64]
Atlas of nonribosomal peptide and polyketide biosynthetic pathways ...
This study demonstrates the widespread distribution of nonribosomal peptide synthetase and modular polyketide synthase biosynthetic pathways across the three ...
[65]
Polyketide Synthase and Nonribosomal Peptide Synthetase Gene ...
Oct 27, 2020 · Major smBGCs in actinomycetes are associated with polyketide synthase (PKS) and/or nonribosomal peptide synthase (NRPS) pathways [4,6].
[66]
The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases
The reaction catalyzed by human HMG-CoA reductase is a target for anti-hypercholesterolemic drugs (statins), which are intended to lower cholesterol levels in ...
[67]
HMG-CoA Reductase Inhibitors - StatPearls - NCBI Bookshelf
... HMG-CoA reductase in the hepatocytes is the first and rate-limiting step in cholesterol biosynthesis. Statins competitively inhibit HMG-CoA reductase enzyme.Continuing Education Activity · Indications · Mechanism of Action · Adverse Effects
[68]
Insight into de-regulation of amino acid feedback inhibition
Aug 23, 2023 · Allosteric feedback inhibition of the committed step in amino acids biosynthetic pathways is thought to maintain homeostasis of end-products [4] ...
[69]
Conserved principles of transcriptional networks controlling ...
Dec 14, 2018 · Gene regulation is intimately connected with metabolism, enabling the appropriate timing and tuning of biochemical pathways to substrate ...<|control11|><|separator|>
[70]
Regulatory architecture determines optimal regulation of gene ... - NIH
Our results suggest that the parameters regulating metabolic enzyme expression are optimized by evolution, under the strong constraint of the underlying ...
[71]
Principles of early drug discovery - PMC - PubMed Central
It is critically important to initiate a drug discovery programme with a small simple molecule as lead optimization, to improve potency and selectivity, ...
[72]
Current status and future directions of high-throughput ADME ...
In this review, we discuss the current state-of-the-art practices in HT-ADME screening including assay portfolio, assay automation, sample analysis, data ...
[73]
Is this a golden age of small-molecule drug discovery?
Oct 30, 2023 · Of the 293 new chemical entities that the FDA approved in 2017–22, 182 were small-molecule drugs. And drug developers are learning new ways to ...Missing: origin | Show results with:origin
[74]
A historical perspective on the discovery of statins - PMC - NIH
The drug showed dramatic activity in lowering LDL cholesterol, with very few side effects. This led Merck to begin large-scale clinical trials of lovastatin in ...Missing: example | Show results with:example
[75]
Discovery: Natural Compound Offers Hope - NCI
Mar 31, 2015 · Paclitaxel was proving to be a very promising discovery in cancer treatment. The chemical structure of Taxol is unique and it looked extremely ...
[76]
Small Molecules in Cancer Therapy: Advances, Challenges, Future
May 31, 2021 · Targeted drugs can be roughly classified into two categories: small molecules and macromolecules (e.g., monoclonal antibodies, polypeptides, ...
[77]
Personalized Medicine: Motivation, Challenges and Progress - PMC
Personalized medicine is rooted in the belief that since individuals possess nuanced and unique characteristics at the molecular, physiological, environmental ...
[78]
Epigenetics-targeted drugs: current paradigms and future challenges
Nov 26, 2024 · Studies have shown the positive effects of using DNMT inhibitors, HDAC inhibitors, and extracellular vesicles loaded with miRNAs in preventing ...
[79]
Clinical efficacy and mechanistic insights of FDA-approved HDAC ...
May 1, 2025 · Several HDAC inhibitors (HDACis) have demonstrated significant anticancer effects, with four FDA-approved molecules—vorinostat, romidepsin, ...
[80]
PROTAC targeted protein degraders: the past is prologue - Nature
Jan 18, 2022 · Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to tackle disease-causing proteins that have ...
[81]
TF-PROTACs Enable Targeted Degradation of Transcription Factors
Jun 8, 2021 · Our results suggest that TF-PROTACs provide a generalizable platform to achieve selective degradation of TFs and a universal strategy for targeting most “ ...<|control11|><|separator|>
[82]
Small Molecules Enhance CRISPR Genome Editing in Pluripotent ...
We have identified small molecules that can enhance CRISPR-mediated HDR efficiency, 3-fold for large fragment insertions and 9-fold for point mutations.
[83]
Small Molecules Targeting MicroRNA for Cancer Therapy - NIH
This review discusses the development, mechanisms and application of small molecules for modulating oncogenic miRNAs (oncomiRs).
[84]
Chem-CRISPR/dCas9 FCPF : a platform for chemically induced ...
Sep 24, 2024 · ... small-molecule epigenetic inhibitors/activators, offering a more flexible and effective method for epigenome editing. Recent studies ...Chem-Crispr/dcas9: A... · Results · Jq1-Pfb-Mediated Complex...
[85]
Chemical and Light Inducible Epigenome Editing - MDPI
Conditional editing platforms controlled by small molecule ligands or light further open up the door for high resolution temporal manipulation and dissection of ...3.3. Light Inducible... · 3.4. Inducible Regulation Of... · 4. Other Inducible...
[86]
Drugging the epigenome in the age of precision medicine
Jan 11, 2023 · Here, we review the promise and pitfalls of epigenetic drug development to date and provide an outlook on recent advances and their promise for future ...
[87]
The rise of epigenetic targets for the development of novel antivirals
Therefore, small molecule inhibition of these enzymes has the potential to block productive lytic infection at a very early stage of infection.Missing: interference | Show results with:interference
[88]
Epigenetic drugs against human DNA viruses and retroviruses
Epigenetic drugs offer an attractive strategy against DNA viruses and retroviruses that establish chronic infections mimicking the chromatinized host genome.Missing: interference | Show results with:interference
[89]
Analysis of Past and Present Synthetic Methodologies on Medicinal ...
Nov 16, 2015 · The analysis revealed that of the current most frequently used synthetic reactions, none were discovered within the past 20 years and only two in the 1980s and ...
[90]
Total Synthesis as a Vehicle for Collaboration
Jul 29, 2019 · The legendary Woodward−Eschenmoser collaboration that led to the total synthesis of vitamin B12 is also discussed. □ INTRODUCTION. One of the ...
[91]
A Case Study of Heterocyclic Suzuki–Miyaura Coupling
Mar 8, 2022 · A review. Suzuki-Miyaura (SM) cross-coupling is arguably the most widely-applied transition metal catalyzed carbon-carbon bond forming reaction ...
[92]
Multicomponent reaction-based combinatorial chemistry for ... - Nature
Apr 4, 2025 · MCRs allow the simultaneous combination of three or more reactants to generate a product in a one-step and efficient manner (Fig. 2a). The MCRs ...
[93]
Multicomponent Reactions Are Accelerated in Water
Two multicomponent reactions, the Ugi and Passerini reactions, are accelerated by the use of aqueous solutions.Supporting Information... · Terms & Conditions · Author Information
[94]
Synthesis and Applications of Small Molecule Libraries
This review focuses on efforts toward the synthesis and evaluation of small organic molecule libraries. Peptide and oligonucleotide libraries will not be ...
[95]
Synthesis of a Small Molecule Combinatorial Library Encoded with ...
... combinatorial chemistry: a review ... A solution-phase strategy for the synthesis of chemical libraries containing small organic molecules: A universal and ...
[96]
[PDF] Catalytic asymmetric synthesis - Nobel Prize
This year's Nobel Prize in Chemistry concerns the development of chiral transition metal catalysts for stereoselective hydrogenations and oxidations - two ...
[97]
Expansion of the Green Chemistry Principles - ACS Publications
Oct 18, 2024 · We therefore propose the following three principles of green chemistry for API production: Understand the supply chain. Fully map and ...
[98]
Flow Chemistry: Recent Developments in the Synthesis of ...
Nov 26, 2015 · In this review we focused our attention only on very recent advances in the continuous flow multistep synthesis of organic molecules which found application as ...<|separator|>
[99]
Flow Chemistry for Flowing Cross-Couplings: A Concise Overview
Feb 6, 2025 · (40) Implementing Suzuki coupling in flow can enhance the efficiency, safety, scalability of the reaction, and, upon a suitable reactor design ...
[100]
High-level semi-synthetic production of the potent antimalarial ...
Apr 10, 2013 · Paddon, C., Westfall, P., Pitera, D. et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496, 528–532 ...
[101]
Metabolic engineering of the shikimate pathway in Amycolatopsis ...
The glycopeptide antibiotics (GPAs), including vancomycin (type I) and teicoplanin (type IV) are important antibiotics in clinical use against multidrug- ...
[102]
Metabolic Engineering for Taxanes Biosynthesis
Oct 24, 2019 · We show that the engineered plants can produce taxadiene and taxadiene-5α-ol, the committed taxol intermediates, at 56.6 μg g −1 FW and 1.3 μg g −1 FW, ...<|control11|><|separator|>
[103]
Enhancement of specialized metabolites using CRISPR/Cas gene ...
Feb 20, 2024 · This article imparts a comprehensive recapitulation of the latest advancements made in the implementation of CRISPR-gene editing techniques.
[104]
Continuous Manufacturing of Small Molecule Drug Substances - ISPE
This article discusses the considerations and approaches adopted by Pfizer, Eli Lilly, GSK, and Amgen in designing and implementing their small molecule drug ...
[105]
Continuous Flow Chemistry: Revolutionizing Pharma Manufacturing
Sep 4, 2024 · From complex challenges to innovative solutions, explore how continuous flow technology is transforming drug substance production efficiency and safety.Missing: GMP | Show results with:GMP
[106]
[PDF] Q13 Continuous Manufacturing of Drug Substances and Drug ... - FDA
In this example, chemical reaction using flow reactors, continuous crystallization, and crossflow filtration are used to obtain the drug substance as a ...<|control11|><|separator|>
[107]
[PDF] Quality Considerations for Continuous Manufacturing Guidance for ...
14. This guidance provides information regarding FDA's current thinking on the quality. 15 considerations for continuous manufacturing of small molecule, solid ...
[108]
https://ispe.org/pharmaceutical-engineering/july-august-2023/continuous-manufacturing-small-molecule-drug-substances
[109]
Scale-Up Process in the API Industry: From Concept to Commercial ...
Aug 18, 2025 · What are the most common challenges in API scale-up? Impurity control, equipment differences, cost management, and regulatory compliance. 4 ...
[110]
Minimum Manufacturing Costs, National Prices, and Estimated ...
The weighted-mean API cost between 2016 and 2020 was estimated to be US $1116/kg; after factoring in the costs of excipients, formulation, tax, and profit, a 10 ...
[111]
Shortening Synthetic Routes to Small Molecule Active ...
Nov 30, 2021 · Biocatalysis, using enzymes for organic synthesis, has emerged as powerful tool for the synthesis of active pharmaceutical ingredients ...
[112]
Life after patent: Drug price dynamics and cost-effectiveness analysis
Jun 12, 2023 · This study analyzed the effects of patent expiration on drug prices in eight countries (US, UK, Cana-da, Australia, Japan, France, Germany, and Switzerland)1. Introduction · 2. Methods · 3. Results<|control11|><|separator|>
[113]
US drug supply chain exposure to China - Brookings Institution
Jul 28, 2025 · Interest in the exposure of U.S. drug supply chains to China surged during the COVID-19 pandemic, as Chinese manufacturing plant closures ...
[114]
COVID-19 is reshaping the pharmaceutical supply chain - C&EN
Apr 27, 2020 · The coronavirus pandemic may mark a rebalancing of where drugs are made as nations recognize a security imperative.